for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Brainstorm Cell Therapeutics Inc

BCLI.O

Latest Trade

14.95USD

Change

0.76(+5.36%)

Volume

285,525

Today's Range

14.13

 - 

15.03

52 Week Range

3.58

 - 

17.20

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.19
Open
14.15
Volume
285,525
3M AVG Volume
13.08
Today's High
15.03
Today's Low
14.13
52 Week High
17.20
52 Week Low
3.58
Shares Out (MIL)
31.53
Market Cap (MIL)
447.38
Forward P/E
-12.45
Dividend (Yield %)
--

Next Event

Q3 2020 Brainstorm Cell Therapeutics Inc Earnings Release

Latest Developments

More

BrainStorm Expands Clinical Pipeline To Evaluate Nurown For Treatment Of Alzheimer's Disease

Sankesh Abbhi Reports 9.04% Stake In Brainstorm Cell Therapeutics Inc As Of March 30 - SEC Filing

Brainstorm Cell Therapeutics And FDA Agree To Potential Nurown Regulatory Pathway For Approval In Als

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Brainstorm Cell Therapeutics Inc

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Industry

Biotechnology & Drugs

Contact Info

1325 Avenue of the Americas Fl 28

NEW YORK, NY

10019-6583

United States

+1.201.4880460

http://www.brainstorm-cell.com/

Executive Leadership

Jacob A. Frenkel

Chairman of the Board

Ralph Kern

President, Chief Medical Officer

Chaim Lebovits

Chief Executive Officer

Irit Arbel

Vice Chairman of the Board

Preetam Shah

Chief Financial Officer, Executive Vice President, Treasurer

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.260

2018

-0.700

2019

-1.060

2020(E)

-1.147
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
42.86
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-662.70
Return on Equity (TTM)
-205.33

Latest News

Latest News

BRIEF-Lineage Cell Therapeutics Announces Extension Of Opregen Development Grant From Israel Innovation Authority

* LINEAGE CELL THERAPEUTICS ANNOUNCES EXTENSION OF OPREGEN DEVELOPMENT GRANT FROM ISRAEL INNOVATION AUTHORITY Source text for Eikon: Further company coverage:

BRIEF-Brainstorm Cell Files Prospectus Supplement Offering 2.5 Mln Shares

* BRAINSTORM CELL THERAPEUTICS FILES PROSPECTUS SUPPLEMENT OFFERING 2.5 MILLION SHARES OF COMMON STOCK - SEC FILING Source text for Eikon: (https://bit.ly/385qybK) Further company coverage:

BRIEF-Lineage Cell Provides Update On OPC1 Cell Therapy Program For Spinal Cord Injury

* LINEAGE CELL THERAPEUTICS PROVIDES UPDATE ON OPC1 CELL THERAPY PROGRAM FOR SPINAL CORD INJURY

BrainStorm to study stem cell treatment in Alzheimer's patients

BrainStorm Cell Therapeutics Inc said on Wednesday it will begin a clinical trial of its experimental stem cell treatment in patients with Alzheimer's disease.

BRIEF-BrainStorm Expands Clinical Pipeline To Evaluate Nurown For Treatment Of Alzheimer's Disease

* BRAINSTORM EXPANDS CLINICAL PIPELINE TO EVALUATE NUROWN FOR THE TREATMENT OF ALZHEIMER'S DISEASE

BRIEF-BrainStorm Cell Therapeutics To Join The Russell 2000 Index And Russell 3000 Index

* BRAINSTORM CELL THERAPEUTICS TO JOIN THE RUSSELL 2000® INDEX AND RUSSELL 3000® INDEX Source text for Eikon: Further company coverage:

BRIEF-Lineage Cell Therapeutics Reinitiates Patient Enrollment In Clinical Study Of Opregen

* LINEAGE CELL THERAPEUTICS REINITIATES PATIENT ENROLLMENT IN CLINICAL STUDY OF OPREGEN® FOR TREATMENT OF DRY AMD WITH GEOGRAPHIC ATROPHY

BRIEF-Lineage Cell Therapeutics Reports First Quarter Results

* LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Lineage Cell Therapeutics Announces Early Exercise Of Option With Cancer Research UK For Immuno-Oncology Cell Therapy Program

* LINEAGE CELL THERAPEUTICS ANNOUNCES EARLY EXERCISE OF OPTION WITH CANCER RESEARCH UK FOR IMMUNO-ONCOLOGY CELL THERAPY PROGRAM

BRIEF-Lineage Cell Therapeutics Conducts Sale Of Shares In Oncocyte Corporation

* LINEAGE CELL THERAPEUTICS CONDUCTS SALE OF SHARES IN ONCOCYTE CORPORATION

BRIEF-Brainstorm Cell Therapeutics - Increased Size Of Board By One Member

* BRAINSTORM CELL THERAPEUTICS INC - ON MARCH 30, 2020, BOARD OF CO INCREASED SIZE OF BOARD BY ONE MEMBER Source text for Eikon: https://bit.ly/344SkmL Further company coverage:

BRIEF-Brainstorm Cell Therapeutics Enters Into Distribution Agreement

* BRAINSTORM CELL THERAPEUTICS INC SAYS ON MARCH 6, ENTERED INTO A DISTRIBUTION AGREEMENT - SEC FILING

BRIEF-Brainstorm Cell Therapeutics And FDA Agree To Potential Nurown Regulatory Pathway For Approval In Als

* BRAINSTORM CELL THERAPEUTICS AND FDA AGREE TO POTENTIAL NUROWN® REGULATORY PATHWAY FOR APPROVAL IN ALS

BRIEF-BrainStorm Cell Therapuetics Reports Q1 Loss Per Share Of $0.12

* BRAINSTORM ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE AND CLINICAL HIGHLIGHTS

BRIEF-Brainstorm Cell Received Good Manufacturing Practice Approval From Israel Ministry Of Health

* BRAINSTORM CELL THERAPUETICS - RECEIVED GOOD MANUFACTURING PRACTICE APPROVAL FROM ISRAEL MINISTRY OF HEALTH FOR ISRAELI CONTRACT MANUFACTURING FACILITY

BRIEF-Brainstorm Granted GMP Certification For Marketing-Level Manufacturing Of NurOwn

* BRAINSTORM GRANTED GMP CERTIFICATION FOR A MARKETING-LEVEL MANUFACTURING OF NUROWN® Source text for Eikon: Further company coverage:

BRIEF-Brainstorm Cell Therapuetics names Eyal Rubin CFO

* Brainstorm strengthens executive team: appoints Eyal Rubin as chief financial officer

BRIEF-Brainstorm reports Q3 loss per share of $0.13

* Q3 loss per share $0.13 Source text for Eikon: Further company coverage:

BrainStorm enrolls first patients in advanced ALS stem cell trial

BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up